Alterations in the expression of β-adrenoceptors and GRKs have been observed in PBMC of patients with cardiovascular diseases such as hypertension or HF (Iaccarino et al., 2005; Penela et al., 2006; Vinge et al., 2007; Agüero et al., 2008, 2012; Oliver et al., 2010; Rengo et al., 2011; Santulli et al., 2011; Montó et al., 2015; Sato et al., 2015), and, in particular, GRK2 has been proposed as a biomarker for the evolution of the HF (Rengo et al., 2016). Here, GRK2 is linked to cardiovascular disorder.